ArticleThrombosis and haemostasis2026
Time Trends in Cause-Specific Mortality in Patients with Pulmonary Embolism Aged 50 Years and Older.
Article in Thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bleeding and Recurrence in Patients with Venous Thromboembolism with Changing Anticoagulant Treatment Patterns: Findings from the TROLL Registry.TH open : companion journal to thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: Patients with pulmonary embolism (PE) have high mortality rates. However, data on cause-specific mortality trends in this population are limited. Aims: To study time trends in cause-specific mortality among PE patients aged ≥50 years, analyzed across three time periods: 2006-2011, 2012-2017, and 2018-2023. The secondary aims included examining mortality trends in matched controls and subgroups of PE patients. Methods: This nationwide Swedish register study included patients with a first-time PE and matched controls. We assessed 30-day and 31- to 365-day cause-specific mortality and employed age- and sex-adjusted Poisson regression for the relative risk (RR) for annual mortality trends. Results: The study comprised 115,476 patients, with cancer as the leading cause of 30-day mortality, stable at 4.7% from 2006-2011 to 2018-2023 (RR 1.00; 95% confidence interval [CI]: 0.99-1.01). Mortality from fatal venous thromboembolism (VTE) decreased from 2.7 to 1.3% (RR 0.94; 95% CI: 0.93-0.95), and cardiovascular disease from 2.3 to 1.1% (RR 0.94; 95% CI: 0.93-0.94). The 31- to 365-day mortality from cancer was stable at 11.8% in 2006-2011 and 11.4% in 2018-2022 (RR 1.00; 95% CI: 0.99-1.00), while mortality due to cardiovascular disease decreased from 4.1 to 2.3% (RR 0.96; CI: 0.95-0.96), and fatal VTE from 0.8 to 0.5% (RR 0.95; 95%: 0.93-0.96). Subgroup analysis showed a decrease in cancer-related mortality among PE patients with known cancer, while it increased in those without known cancer. Conclusion: Cancer was the leading cause of death in PE patients aged ≥50 years, with stable rates over time due to contrasting trends in patients with and without known cancer. Fatal VTE comprised a minor percentage of overall mortality in recent years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.